查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197680

支原体检测市场——增长、趋势、COVID-19 影响和预测 (2023-2028)

Mycoplasma Testing Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在 2022 年至 2027 年的预测期内，支原体检测市场预计将以 13% 的复合年增长率稳步增长。

最近，各国都面临着 COVID-19 的巨大威胁。 根据世界卫生组织（WHO）的说法，冠状病毒病是一种传染病，大多数人在感染 COVID-19 病毒后会出现轻度至中度的呼吸道疾病。 2022 年 4 月发表的一项名为“COVID-19 大流行之前和期间北京儿童肺炎支原体流行情况”的研究指出，肺炎球菌流行于 2019 年夏季在北京开始。 在 2019 年底爆发 COVID-19 大流行之后，肺炎支原体流行率急剧下降。 这是因为 COVID-19 大流行的限制措施有效地抑制了肺炎支原体的传播。 然而，在放鬆对 COVID-19 的管制后，肺炎支原体预计在研究期间将进一步增加，从而影响市场增长。

生物製药公司在研发活动上的高支出、政府对研究活动的承诺和资助的增加、技术进步、对快速、准确和廉价测试的需求增加、细胞培养物污染增加等因素进一步推动了支原体检测市场.

在 2021 年 10 月发表的“使用淬灭探针聚合□链反应对大环内酯敏感性进行肺炎支原体即时分子诊断”的研究中，Smart Gene 系统能够检测到肺炎支原体的存在以及肺炎支原体的 23S rRNA肺炎支原体。它被描述为一种快速准确的检测方法，用于同时检测基因域 V 中的点突变。 Smart Gene 系统适用于医院和门诊即时检测。 因此，此类研究展示了肺炎支原体的潜在诊断测试，将扩大其接受度并推动市场。

2022 年 4 月，Alpha Biolabs 推出了面向公众和医疗保健合作伙伴的 STI 测试。 The Complete Panel (7 STIs) detects Chlamydia, Gonorrhea, Mycoplasma genitalium, Mycoplasma hominis, Trichomonas, Ureaplasma parvum (UTI), and Urea urealyticum (UTI) bacteria. Detects urea urea, trichomonas (UTI) 细菌。 因此，检测支原体细菌的检测试剂的推出将提振市场。 因此，由于上述因素，该研究涵盖的市场预计在研究期间将显着增长。 然而，多个发达国家和新兴国家都有一定的严格政府法规，新进入者的高度整合是支原体检测市场增长的主要製约因素之一。

支原体检测市场趋势

聚合□链反应 (PCR) 预计在预测期内将占据重要的市场份额

北美目前在支原体检测市场占据主导地位，预计未来几年仍将如此。 由于该地区完善的医疗保健行业和呼吸系统疾病患病率上升，预计该地区未来的市场份额将增加。 其他增长因素包括全球生物技术和製药公司的存在以及该地区研发活动投资的增加。 在北美，美国占据了大部分市场份额。 这是由于即时检测的迅速采用以及不断上升的医疗保健成本。

此外，该产品在该国的推出将增加支原体检测程序，促进市场增长。 例如，2020 年 7 月，生物梅里埃针对生物治疗药物（抗体、激素、细胞和基因治疗等）中使用的药物（抗体、激素、细胞和基因治疗等）推出了支原体检测的创新测试，这是製药行业最具活力的领域之一。药物“BIOFIRE MYCOPLASMA ”在美国推出。 此外，2020 年 4 月，Infinity Laboratories 启动了支原体检测并扩展了其能力。 这种关键战略的采用，如扩张、合作伙伴关係和收购，扩大了主要市场参与者的能力，从而推动了市场增长。

此外，越来越多的研发研究证明了美国诊断技术的有效性，预计将在研究期间推动市场增长。 例如，2021 年 1 月，富士胶片和先进生物创新与製造中心将在马萨诸塞州投资约 7600 万美元，用于细胞和基因治疗、基因编辑、免疫治疗和生物技术领域的先进研发工作。 因此，由于上述因素，预计研究期间该地区的市场将显着增长。

预计在预测期内北美将占据重要的市场份额

北美目前在支原体检测市场占据主导地位，预计未来几年仍将保持主导地位。 由于成熟的医疗保健行业和呼吸系统疾病患病率上升，预计该地区的市场份额将增加。 其他增长因素包括全球生物技术和製药公司的存在以及该地区研发活动投资的增加。 在北美，美国占据了大部分市场份额。 这是由于即时检测的迅速采用以及不断上升的医疗保健成本。

此外，该产品在该国的推出将增加支原体检测程序，促进市场增长。 例如，2020 年 7 月，生物梅里埃推出了一项创新测试，用于检测生物治疗药物（抗体、激素、细胞和基因疗法等）中使用的支原体，这是製药行业最具活力的领域之一。“BIOFIRE 支原体”在美国发售。

此外，2020 年 4 月，Infinity Laboratories 开始测试支原体并扩展其能力。 扩张、合作伙伴关係和收购等关键战略的采用扩大了主要市场参与者的能力，从而推动了市场增长。

此外，在美国不断增加的研发证明诊断技术的有效性预计将在研究期间推动市场增长。 例如，根据 2020 年 5 月发表的“检测和测定肺炎支原体大环内酯耐药性的商业分子诊断方法评估”研究，InGenius PCR (99.5%) 和 FilmArray RP (98.1%) 显示临床敏感性最高确认的。 因此，日本有效诊断技术的存在有望推动支原体检测并最终推动市场发展。 因此，由于上述因素，预计研究期间该地区的市场将显着增长。

支原体检测市场竞争对手分析

市场竞争适中。 公司正在专注于各种增长战略，例如新产品发布、联盟、收购和合作伙伴关係，以增加他们的市场占有率。 主要参与者包括 Abbott、Agilent Technologies、Charles River Laboratories International Inc.、Eurofins Scientific、F. Hoffmann-La Roche Ltd、Lonza Group、Merck KGaA、PromoCell GmbH、Sartorius AG 和 Thermo Fisher Scientific Inc. 等公司。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 增加政府对研究活动的承诺和资助
    • 对快速、准确且经济实惠的测试的需求增加
    • 细胞培养污染增加
  • 市场製约因素
    • 漫长而费力的检查过程
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：单位：百万美元）

  • 按产品分类
    • 乐器
    • 试剂盒和试剂
  • 按技术
    • 聚合□链反应
    • ELISA 方法
    • □法
    • DNA 染色
    • 其他技术
  • 通过申请
    • 细胞系检测
    • 生物生产测试
    • 其他应用
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Agilent Technologies
    • ATCC
    • Bionique Testing Laboratories Inc.
    • Charles River Laboratories International Inc.
    • Eurofins Scientific
    • Lonza Group Ltd
    • Merck KGaA
    • Bionique Testing Laboratories Inc.
    • PromoCell GmbH
    • Thermo Fisher Scientific Inc.
    • AdvaCare
    • Sartorius AG

第7章 市场机会与今后动向

简介目录
Product Code: 51949

The mycoplasma testing market is estimated to register a healthy CAGR of 13% over the forecast period, 2022-2027.

In recent times, countries have faced a huge threat of COVID-19. As per the World Health Organization (WHO), coronavirus disease is an infectious disease, and most people infected with the COVID-19 virus will experience mild to moderate respiratory illness. The study "The Prevalence of Mycoplasma Pneumoniae Among Children in Beijing Before and During the COVID-19 Pandemic" published in April 2022, stated that the M. pneumoniae outbreak started in the summer of 2019 in Beijing. After the COVID-19 pandemic outbreak at the end of 2019, the M. pneumoniae positive rates dropped dramatically. This was due to the restrictive measures of the COVID-19 pandemic, which effectively controlled the transmission of M. pneumonia. However, after the easing of COVID-19 restrictions, M. pneumonia is expected to increase further during the study period, thereby impacting the market growth.

Factors such as high spending in R&D activities by biopharmaceutical companies, increased government initiatives and funding in research activities, technological advancements, increasing demand for fast, accurate, and affordable testing, and the increasing cell culture contamination, are further driving the market for mycoplasma testing.

The study "Point-of-care molecular diagnosis of Mycoplasma pneumonia including macrolide sensitivity using quenching probe polymerase chain reaction" published in October 2021, stated that the Smart Gene system is a rapid and accurate assay for detection of the existence of M. pneumoniae and a point mutation at domain V of the 23S rRNA gene of M. pneumoniae at the same time. The Smart Gene system is suitable for point-of-care testing in both hospital and outpatient settings. Thus, such studies indicating the potential of diagnostic testing for mycoplasma pneumonia will increase their acceptance, thus driving the market.

In April 2022, AlphaBiolabs launched STI testing for members of the public and healthcare partners. The Complete Panel (7 STIs) detects chlamydia, gonorrhea, mycoplasma genitalium, mycoplasma hominis, trichomoniasis, and ureaplasma parvum (UTI), and urea urealyticum (UTI) bacterias. Therefore, the launch of such tests detecting mycoplasma bacteria will boost the market. Thus, due to the above-mentioned factors, the studied market is expected to grow significantly during the study period. However, there are certain stringent government regulations across several developed and emerging countries and a high degree of consolidation for new entrants, which are among the major hindrances in the growth of the mycoplasma testing market.

Mycoplasma Testing Market Trends

Polymerase Chain Reaction (PCR) is Expected to Hold a Significant Market Share Over the Forecast Period

North America currently dominates the mycoplasma testing market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future due to its well-established healthcare industry and the rising prevalence of respiratory diseases in the area. Other factors driving the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment in R&D activities in the region. The United States holds the majority of the market share in North America. This is due to the rising healthcare expenditure, along with the rapid adoption of point-of-care testing.

The launch of products in the country will also increase the mycoplasma testing procedures contributing to the market growth. For instance, in July 2020, bioMerieux launched BIOFIRE MYCOPLASMA, an innovative test for mycoplasma detection in the United States for pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry. Furthermore, in April 2020, Infinity Laboratories expanded its capabilities by launching Mycoplasma testing. Such adoption of critical strategies like expansion, partnerships, acquisitions, and others will expand the capabilities of the key market players, thereby driving the market growth.

Moreover, rising research and development studies proving the efficacies of diagnostic techniques in the United States are expected to drive market growth during the study period. For instance, in January 2021, Fujifilm and the Center for Advanced Biological Innovation and Manufacturing are investing about USD 76 million in Massachusetts for advanced research and development in cell and gene therapy, gene editing, immunotherapy, and biotechnology. Thus, owing to the above-mentioned factors, the studied market is expected to grow significantly in the region during the study period.

North America is Expected to Occupy a Significant Market Share Over the Forecast Period

North America currently dominates the mycoplasma testing market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share due to its well-established healthcare industry and the rising prevalence of respiratory diseases. Other factors driving the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment in R&D activities in the region. The United States holds the majority of the market share in North America. This is due to the rising healthcare expenditure, along with the rapid adoption of point-of-care testing.

Launching products in the country will also increase the mycoplasma testing procedures contributing to the market growth. For instance, in July 2020, bioMerieux launched BIOFIRE MYCOPLASMA, an innovative test for mycoplasma detection in the United States for pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry.

Furthermore, in April 2020, Infinity Laboratories expanded its capabilities by launching Mycoplasma testing. Such adoption of key strategies like expansion, partnerships, acquisitions, and others will expand the capabilities of the key market players, thereby driving market growth.

Moreover, rising research and development studies proving the efficacies of diagnostic techniques in the United States are expected to drive market growth during the study period. For instance, according to the study "Evaluation of Commercial Molecular Diagnostic Methods for Detection and Determination of Macrolide Resistance in Mycoplasma pneumonia" published in May 2020, the highest clinical sensitivities were found with the InGenius PCR (99.5%) and the FilmArray RP (98.1%). Therefore, the presence of effective diagnostic techniques in the country is expected to boost mycoplasma testing and, in turn, is expected to drive the market. Thus, owing to the factors mentioned above, the studied market is expected to grow significantly in the region during the study period.

Mycoplasma Testing Market Competitor Analysis

The studied market is moderately competitive. Companies are focusing on various growth strategies, such as new product launches, collaborations, acquisitions, and partnerships, to enhance their market presence. The major players include Abbott, Agilent Technologies, Charles River Laboratories International Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Lonza Group, Merck KGaA, PromoCell GmbH, Sartorius AG, and Thermo Fisher Scientific Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increased Government Initiatives and Funding in Research Activities
    • 4.2.2 Increasing Demand for Fast, Accurate, and Affordable Testing
    • 4.2.3 Increasing Cell Culture Contamination
  • 4.3 Market Restraints
    • 4.3.1 Long and Laborious Detection Process
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Product
    • 5.1.1 Instruments
    • 5.1.2 Kits and Reagents
  • 5.2 By Technology
    • 5.2.1 PCR
    • 5.2.2 ELISA
    • 5.2.3 Enzymatic Methods
    • 5.2.4 DNA Staining
    • 5.2.5 Other Technologies
  • 5.3 By Application
    • 5.3.1 Cell Line Testing
    • 5.3.2 Bioproduction Testing
    • 5.3.3 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 ATCC
    • 6.1.3 Bionique Testing Laboratories Inc.
    • 6.1.4 Charles River Laboratories International Inc.
    • 6.1.5 Eurofins Scientific
    • 6.1.6 Lonza Group Ltd
    • 6.1.7 Merck KGaA
    • 6.1.8 Bionique Testing Laboratories Inc.
    • 6.1.9 PromoCell GmbH
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 AdvaCare
    • 6.1.12 Sartorius AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS